Clinical phenotypes of SARS-CoV-2
Patients with COVID-19 present a broad spectrum of clinical presentation. Whereas hypoxaemia is the marker of severity, different strategies of management should be customised to five specific individual phenotypes. Many intubated patients present with phenotype 4, characterised by pulmonary hypoxic...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:225257 |
| Acceso en línea: | https://ddd.uab.cat/record/225257 https://dx.doi.org/urn:doi:10.1183/13993003.01028-2020 |
| Access Level: | acceso abierto |
| Palabra clave: | ARDS SARS-CoV-2 COVID-19 Acute Lung Injury Betacoronavirus Biomarkers Biomedical Research Coronavirus Infections Disease Management Female Humans Hypoxia Lung Compliance Male Mechanical ventilation Pandemics Personalized medicine Phenotype Pneumonia, Viral Procalcitonin SARS Virus |
| Sumario: | Patients with COVID-19 present a broad spectrum of clinical presentation. Whereas hypoxaemia is the marker of severity, different strategies of management should be customised to five specific individual phenotypes. Many intubated patients present with phenotype 4, characterised by pulmonary hypoxic vasoconstriction, being associated with severe hypoxaemia with "normal" (>40 mL·cmH2O-1) lung compliance and likely representing pulmonary microvascular thrombosis. Phenotype 5 is often associated with high plasma procalcitonin and has low pulmonary compliance, Which is a result of co-infection or acute lung injury after noninvasive ventilation. Identifying these clinical phenotypes and applying a personalised approach would benefit the optimisation of therapies and improve outcomes. |
|---|